Baseline sampling [Regulatives / Guidelines]

posted by NK – India, 2019-06-26 07:25 (667 d 06:22 ago) – Posting: # 20360
Views: 2,292

Hello everyone,

I have a question with regards to FDA OGD guidance of Dihydroergotamine Nasal Spray" dated February 2019.

The guidance specified that "baseline corrected PK data of AUC and Cmax should be used for bio-equivalence calculation"

As per my understanding, Dihydroergotamine is neither endogenous nor available in the diet, then why baseline value is required?

If it is required, what should be baseline sampling time points (-1h or -30 min or -15 min ...)?

Thanks in advance.

Regards
NK


Edit: URL corrected. [Helmut]

Complete thread:

Activity
 Admin contact
21,429 posts in 4,479 threads, 1,512 registered users;
online 12 (0 registered, 12 guests [including 3 identified bots]).
Forum time: Friday 13:48 CEST (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5